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A B S T R A C T
Purpose
To determine the association between tumor hypoxia, treatment regimen, and locoregional failure
(LRF) in patients with stage III or IV squamous cell carcinoma of the head and neck randomly
assigned to radiotherapy (70 Gy in 35 fractions over 7 weeks) plus either tirapazamine and cisplatin
in weeks 1, 4, and 7 and tirapazamine alone in weeks 2 and 3 (TPZ/CIS) or cisplatin and infusional
fluorouracil during weeks 6 and 7 (chemoboost).
Patients and Methods
Forty-five patients were enrolled onto a hypoxic imaging substudy of a larger randomized trial.
Pretreatment and midtreatment [18F]-fluoromisonidazole positron emission tomography scans
(FMISO-PET) were performed 2 hours after tracer administration, with qualitative scoring of
uptake in both primary tumors and nodes.
Results
Thirty-two patients (71%) had detectable hypoxia in either or both primary and nodal disease. In
patients who received chemoboost, one of 10 patients without hypoxia had LRF compared with
eight of 13 patients with hypoxia; the risk of LRF was significantly higher in hypoxic patients (exact
log-rank, P  .038; hazard ratio [HR]  7.1). By contrast, in patients who received the TPZ/CIS
regimen, only one of 19 patients with hypoxic tumors had LRF; risk of LRF was significantly higher
in chemoboost patients (P .001; HR 15). Similarly, looking at the primary site alone, in patients
with hypoxic primaries, zero of eight patients treated with TPZ/CIS experienced failure locally
compared with six of nine patients treated with chemoboost (P  .011; HR  0).
Conclusion
Hypoxia on FMISO-PET imaging, in patients receiving a nontirapazamine-containing chemoradiother-
apy regimen, is associatedwith a high risk of LRF. Our data provide the first clinical evidence to support
the experimental observation that tirapazamine acts by specifically targeting hypoxic tumor cells.
J Clin Oncol 24:2098-2104. © 2006 by American Society of Clinical Oncology
INTRODUCTION
The potential importance of tumor hypoxia as a
cause of treatment failure in patients treated with
radiation has been recognized for a long time.1 In
particular, studies using oxygen-sensitive needle
electrodes in patients with head and neck cancer
treated with primary radiation therapy have shown a
correlation between the presence of hypoxia and de-
creased locoregional control.2,3 However, progress has
been hampered by the significant limitations of previ-
ously available methods of hypoxia detection and by
the limitedbenefit seenwith treatment strategies tested
to overcome hypoxia (eg, hypoxic cell sensitizers and
hyperbaric oxygen).4
Hypoxia-activated prodrugs represent a new
strategy to exploit the presence of hypoxia inhuman
tumors. One such compound is tirapazamine, a
benzotriazine compound, which acts as a hypoxic
cytotoxin and potentiates both radiation and cispla-
tin cytotoxicity.5-7 Because the addition of concur-
rent platinum-based chemotherapy to radiation has
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been demonstrated to improve locoregional control and overall sur-
vival in patients with locoregionally advanced head and neck
cancer,8-10 we developed a regimen in which tirapazamine was added
to a standard radiation and cisplatin regimen (TPZ/CIS). Promising
results were seen in the initial trial,11 which led to testing of this
regimen in a cooperative group randomized phase II trial (Trans-
TasmanRadiationOncologyGroup[TROG]98.02) conductedunder
the auspices of TROG.12 The other regimen tested was the chemo-
boost regimen, which seems to have similar efficacy to other
platinum-based concurrent chemoradiotherapy regimens.13-15 We
have previously reported the overall results of this trial; 122 patients
were enrolled, and both regimens were found to be feasible, with
acceptable toxicity profiles in the cooperative group setting.12 Three-
year failure-free survival rates were 55% (95% CI, 39% to 70%) with
TPZ/CIS and44%(95%CI, 30%to60%)with chemoboost (log-rank
test, P .16). Three-year locoregional failure (LRF) –free rates were
84% (95% CI, 71% to 92%) in the TPZ/CIS arm and 66% (95% CI,
51% to79%) in the chemoboost arm (P .069).Given the promising
efficacy seen in this trial, TPZ/CIS is being evaluated in two large
international phase III trials.
Aspart of theTROG98.02 trial, patients treatedatone center, the
Peter MacCallum Cancer Centre (PMCC), were also enrolled onto a
hypoxic imaging substudy with serial [18F]-fluoromisonidazole
(FMISO)positron emission tomography (PET) scans.Wenowreport
the results of this hypoxic imaging study.
PATIENTS AND METHODS
Study Design and Eligibility
Thiswas a substudyof anopen-label, randomized, phase II trial studying
two concurrent chemoradiotherapy regimens that was conducted under the
auspices of the TROG. All patients enrolled onto the randomized trial at a
single institution, PMCC, were eligible and provided written informed con-
sent to participate in this FMISO-PET substudy.
Eligibility criteria for theTROG98.02 trial includedpreviouslyuntreated
squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or
larynx; stage III or IVdisease (excludingT1N1anddistantmetastases); andno
concurrent active cancer in the last 5 years. The PMCC ethics committee
approved the protocol, which included this imaging substudy.
Pretreatment Evaluations
Before enrollment, all patients underwent a full history, physical
examination, blood tests, computed tomography (CT) or magnetic reso-
nance imaging scan of the head and neck, chest x-ray (CT of the chest if
involved low neck nodes), and PET scan with [18F]-fluorodeoxyglucose
(FDG-PET) and FMISO-PET.
PET
Scans for tumor hypoxia (FMISO-PET)were performed at baseline and
at weeks 4 to 5 during treatment. If there was residual hypoxia present on the
week 4 to 5 scan, then it was to be repeated at the end of treatment. Static
high-resolution mode images of the neck were acquired at 2 hours after
radiotracer administration. All PET imaging was performed on a dedicated
PET scanner (PENN-PET 300H; UGM Medical System Inc, Philadelphia,
PA). On each occasion, PET images of the neck were acquired and processed
using measured attenuation correction and iterative reconstruction in treat-
ment position.16 After coregistrationwith a baseline FDG-PET study, tumoral
regions of interest were applied for analyses of FMISO uptake in the primary
and nodal sites. FMISO-PET lesions were scored qualitatively by consensus of
two readers blinded to CT results, according to the following scheme as
previously published17: 0, uptake less than background; 1, no regions of focal
uptake greater than background; 2, focal uptake mildly greater than back-
ground; 3, focal uptake moderately greater than background; and 4, focal
uptake markedly greater than background.
However, unless FMISO uptake was as intense as FDG uptake qualita-
tively, a score of 4 could not be given. The FMISO scan was interpreted to be
positive if therewas greater activity (score of 2 or 3)within the sites of tumoral
uptakeof FDGthan the activity present in adjacent ormirrored soft tissue sites
on the 2-hour images when reviewed using a linear rainbow color scale.
Treatment Plan
Arm 1. Tirapazamine was supplied by Sanofi-Aventis Pharmaceuticals
(Sydney, Australia). On day 2 of weeks 1, 4, and 7, tirapazamine (290mg/m2)
was administeredover 2hours, followed1 hour later by cisplatin (75mg/m2)
over 1 hour, followed immediately by radiotherapy. In addition, tira-
pazamine (160 mg/m2) was administered before radiation three times a
week in weeks 2 and 3.
Arm2. Cisplatin (50mg/m2)was administered before radiotherapy on
day 1 of weeks 6 and 7 of radiotherapy. Fluorouracil (360 mg/m2/d) was
administered by continuous infusion from days 1 to 5 (120-hour infusion) in
weeks 6 and 7 of radiotherapy.
Radiation Therapy
Planned radiation therapywas 70Gy in 35 fractions over 7weeks in both
arms. The radiation was administered via a shrinking-field technique. The
initial 50 Gy encompassed the gross clinical disease and sites suspected of
harboring subclinical disease. The maximal spinal cord dose was 45 Gy. The
fields were then reduced in size to treat the areas of gross macroscopic disease
to 70 Gy, with a buffer zone of 60 Gy around larger nodal masses.
Random Assignment and Stratification
Patients were randomly assigned 1:1 to the two arms and stratified by
institution, as previously described. For patients in the imaging substudy, the
result of the baseline FMISO-PET was not a stratification factor.
End Points
Failure was defined as persistent disease in the primary site, progression
of disease in the neck (in patients not undergoing planned neck dissection),
residual disease left behind after neck dissection (if performed), locoregional
relapse after complete response, or distant metastasis. Time to LRF was mea-
sured from random assignment to the date of LRF, and failure-free survival
was measured from random assignment to the date of first failure or death.
Both timeswere censored by the close-out date; time to LRFwas also censored
by distant metastasis and death without preceding failure.
Statistical Methods
Analyses of time to LRF and failure-free survival are based on the intent-
to-treat policy. A close-out date ofMay 20, 2004was used for this analysis. The
Kaplan-Meier method was used to estimate time to event curves. Log-rank
(exact) test andCoxproportionalhazards regressionwereused toanalyze time
to event data. Two-sided tests were used throughout. No formal adjustment
for multiple comparisons was made.
Role of the Funding Source
Sanofi-Aventis partially supported the study but was not the sponsor of
this trial, which was conducted by TROG. Sanofi-Aventis was involved in
monitoring the source data but was not involved in the study design, database
entry, analysis, interpretation of data, writing of the report, or decision to
submit the paper for publication.
RESULTS
Patient Characteristics
Fifty-three of 122 patients enrolled onto the TROG 98.02 ran-
domized trial were treated at PMCC. Forty-five of these 53 patients
participated in the hypoxic imaging substudy. In the remaining eight
patients, FMISO-PET could not be performed before they com-
menced treatment because of unavailability of the tracer or the PET
scanner.Themedianpotential follow-up time for the45patients from
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commencing treatment to the close-out date was 3.6 years (range, 1.8
to 5.7 years). Baseline patient characteristicswere reasonably balanced
between patients on the two arms, although there was a higher inci-
dence of node-positive andN3 disease in the TPZ/CIS arm (Table 1).
Hypoxia in the Primary Tumor and/or Nodes
Thirty-two (71%) of 45 patients had detectable hypoxia in the
primary tumor and/or a lymph nodalmetastasis (Table 2). In only six
patients was hypoxia detected in both the primary tumor and a node.
Of the seven patients with node-negative disease, only one had hyp-
oxia evident in the primary tumor.
For the purposes of assessing the correlation between hypoxia,
treatment arm, and outcome, patients were divided into four groups based on treatment armand the presence or absence of hypoxia in the
primary tumor and/or nodes (Table 2). Because random assignment
was not stratified by hypoxia status, it is not surprising that the distri-
bution between the four groups turned out to be unbalanced.
The complete response rates were 70% (seven of 10 pa-
tients) for chemoboost without hypoxia, 31% (four of 13 pa-
tients) for chemoboost with hypoxia, 100% (three of three
patients) for TPZ/CIS without hypoxia, and 74% (14 of 19
patients) for TPZ/CIS with hypoxia.
In patients who received the chemoboost regimen, LRF was
uncommon inpatientswithouthypoxia but common inpatientswith
hypoxia (Table 3). The risk of LRF in patients who received chemo-
boost was significantly higher in hypoxic patients (exact log-rank,
P  .038; hazard ratio [HR]  7.1). By contrast, in patients with
hypoxic tumors, only one of 19 patients who received TPZ/CIS expe-
rienced LRF comparedwith eight of 13 patients who received chemo-
boost. In patients with hypoxic tumors, risk of LRF was significantly
higher in chemoboost patients compared with patients who received
TPZ/CIS (P  .001; HR  15). Figure 1 demonstrates a differential
response in an individual patient treated with chemoboost who
achieved a complete response in thenonhypoxic primary tumor anda
poor response in the hypoxic node.
Similar trendswere seen for failure-free survival. In patients who
received chemoboost, failure-free survival timewas shorter inhypoxic
patients (exact log-rank,P .095;HR3.2). Inpatientswithhypoxic
tumors, risk of failure or deathwas significantly higher in chemoboost
patients compared with TPZ/CIS patients (exact log-rank, P .004;
HR 4.7). In patients with hypoxic tumors, overall survival timewas
shorter in chemoboost patients comparedwithTPZ/CIS patients (ex-
act log-rank, P .11; HR 2.45).
Surprisingly, two of three patientswithout hypoxiawho received
TPZ/CIS experienced LRF. It is difficult to draw any conclusions
about this group with such small numbers. Both cases of LRF were
Table 1. Baseline Characteristics by Treatment Arm
Characteristic
Total
No. of
Patients
Treatment Arm
TPZ/CIS Chemoboost
No. of
Patients %
No. of
Patients %
All patients 45 22 100 23 100
Median age, years 57 56
Sex
Male 36 17 77 19 83
Female 9 5 23 4 17
Primary site of disease
Oral cavity 3 1 5 2 9
Oropharynx 27 14 64 13 57
Hypopharynx 8 4 18 4 17
Larynx 7 3 14 4 17
Tumor stage
T1 7 5 23 2 9
T2 7 3 14 4 17
T3 21 10 45 11 48
T4 10 4 18 6 26
Node stage
N0 7 2 9 5 22
N1 7 2 9 5 22
N2a 3 3 14 0 0
N2b 13 6 27 7 30
N2c 6 3 14 3 13
N3 9 6 27 3 13
Node involvement
Negative 7 2 9 5 22
Positive 38 20 91 17 74
Disease stage
III 12 4 18 8 35
IV 33 18 82 15 65
ECOG performance status
0 15 12 55 13 57
1 18 9 41 9 39
2 2 1 5 1 4
Hemoglobin group
Low 9 6 27 3 13
High 36 16 73 20 87
Baseline hypoxia
None 13 3 14 10 43
Primary tumor only 11 4 18 7 30
Node only 15 11 50 4 17
Primary tumor and node 6 4 18 2 9
Abbreviations: TPZ/CIS, tirapazamine and cisplatin; ECOG, Eastern Coopera-
tive Oncology Group.
Table 2. Primary Tumor Versus Node Hypoxia
Primary
Hypoxia
Node Negative
(No. of patients)
Node Hypoxia (No.
of patients)
Total
(No. of patients)
No
Hypoxia Hypoxia
No hypoxia 6 7 15 28
Hypoxia 1 10 6 17
Total 7 17 21 45
Table 3. Locoregional Failure by Treatment Arm and Hypoxia
Hypoxia Status
Treatment
Chemoboost TPZ/CIS
No. of
Locoregional
Failures
No. of
Patients
No. of
Locoregional
Failures
No. of
Patients
Nonhypoxic 1 10 2 3
Hypoxia in primary tumor
and/or nodes
8 13 1 19
Abbreviation: TPZ/CIS, tirapazamine and cisplatin.
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unusual. In one case, a patient with a T3N0 soft palate tumor had a
marginal relapse with infraorbital nerve infiltration. In the other case,
a patient with a T4N2b tonsillar fossa tumor died of unrelated causes
17 months after completing treatment. At autopsy, there was micro-
scopic evidenceof residual cancer at theprimary site that hadnotbeen
detected antemortem.
Hypoxia in the Primary Tumor
We also examined the impact of hypoxia in the primary tumor
on local control (Fig2). Inpatients treatedwithchemoboost, oneof14
patients without hypoxia experienced failure locally compared with
six of nine patients with a hypoxic primary tumor. Risk of primary
failure was significantly higher for hypoxic patients (exact log-rank,
Fig 1. (A) Baseline [18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) of patient with T2N2b squamous cell carcinoma of the pyriform fossa with
left nodal mass. (B) [18F]-fluoromisonidazole (FMISO) -PET at baseline, nonhypoxic primary tumor, and hypoxic node. (C) FDG-PET 12 weeks after chemoboost,
complete response in nonhypoxic primary tumor, and poor response in hypoxic node. Residual tumor in nodal mass was confirmed pathologically after neck dissection.
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P  .015; HR  8.9). For patients with hypoxic primary tumors
treated with TPZ/CIS, zero of eight patients experienced failure
locally comparedwith six of nine patients treatedwith chemoboost
(P .011; HR 0.0).
Three patients with recurrent/persistent disease at the primary
site underwent salvage surgery. All three patients were on the chemo-
boost arm, with two of the three patients having baseline hypoxia in
the primary tumor.
Hypoxia in the Nodes
Four of 38 node-positive patients have experienced failure in the
nodes; three of these patients were treated with chemoboost, and one
was treatedwithTPZ/CIS (one of 12 patients on chemoboostwithout
hypoxia in nodes, two of six patients on chemoboost with hypoxic
nodes, zero of five patients without hypoxia on TPZ/CIS, and one of
15 patients with hypoxia on TPZ/CIS).
Residual Hypoxia
Twenty-nine of 32 patients with baseline hypoxia in the primary
tumor and/or in a node had a repeat FMISO-PET in weeks 4 to 5. Six
patients had residual hypoxia detected. Four (two primary and two
nodal) of 13 patients with baseline hypoxia treated with chemoboost
had residual hypoxia, and all experienced LRF (Table 4). Two (both
nodal) of 16 patients with baseline hypoxia treated with TPZ/CIS had
residual hypoxia, with neither experiencing LRF but both developing
distant metastases.
Distant Failure
Nine of 45 patients (six treated with chemoboost, and three
treated with TPZ/CIS) experienced failure at distant sites as a compo-
nent of first failure. It is of interest that eight of 32 patients with
baseline hypoxia experienced distant metastasis as first failure
compared with only one of 13 patients without baseline hypoxia
(HR 3.42; P .29).
DISCUSSION
In this study,we have demonstrated that baseline hypoxia, as detected
by FMISO-PET imaging, is associated with a high risk of LRF in
patients treated with a platinum/fluorouracil-based chemoradiother-
apy regimen. Conversely, there is a striking improvement in locore-
gional control in patients with hypoxic tumors treated with the
tirapazamine-containing regimen compared with the chemoboost
regimen. Furthermore, the absence of hypoxia on FMISOwas associ-
atedwith a low risk of LRFwhen treatedwith chemoboost, suggesting
that this group of patients does not require more intensive therapy.
In preclinical studies, tirapazamine exhibits differential cytotox-
icity under hypoxic comparedwith aerobic conditions in the range of
15- to 200-fold.18 However, it has been difficult to confirm that tira-
pazamine does indeed elicit specific hypoxic cytotoxicity in human
tumors. No single-agent activity was observed in phase I clinical tri-
als,19 and all subsequent phase II and III trials used tirapazamine in
combination with chemotherapy20 or radiation.12 As part of a trial
conducted at Stanford University (Palo Alto, CA), patients with head
and neck cancer had oxygen levels in a lymph node measured by a
needle electrode and then had a fine-needle aspirate taken from the
node before and after a dose of tirapazamine.21 Single-strand DNA
breaks in the aspirated cells were measured by the comet assay. It was
demonstrated that tirapazamine does cause DNA damage in human
tumor cells, but there was no correlation between oxygen measure-
ments and comet tail moment. Therefore, our data provide the first
clinical evidence to confirm the experimental observation that tira-
pazamine acts by specifically targeting hypoxic tumor cells.
Previous studies demonstrating an adverse prognosis in hypoxic
head and neck cancers treated with radiation have been performed
mainly with oxygen-sensitive electrodes.2,3,22-25 This technology has a
number of limitations, including its invasive nature (which makes it
difficult to access primary head and neck tumors), the inability to
distinguish readings from necrotic tissue versus viable hypoxic cells,
interoperator variability, and the limited number of centers with the
necessary equipment and technical expertise.4,26,27 In most of the
studies with oxygen-sensitive electrodes, the measurements of hyp-
oxiawerepredominantly taken fromthemoreaccessible lymphnodes
rather than from the primary tumors.3,22-25 However, in one study
involving 15 patients, a good correlation was found between oxygen
measurements in the primary tumor and in a node.28 In contrast, we
found that the presence of hypoxia in node-positive patients may
frequentlybediscordantbetween theprimary tumorandthenodes. In
only13of38node-positivepatientswas thehypoxia statusconcordant
Fig 2. Time to local failure (Kaplan-Meier method) by treatment arm and hypoxia
in the primary tumor (censored times are indicated as tick marks on the curves).
Cis, cisplatin; FU, fluorouracil; TPZ, tirapazamine.
Table 4. Locoregional Failure by Treatment Arm and Resolution of Hypoxia
Hypoxia Status
Treatment
Chemoboost TPZ/CIS
No. of
Locoregional
Failures
No. of
Patients
No. of
Locoregional
Failures
No. of
Patients
No residual hypoxia 4 9 0 14
Residual hypoxia in
primary tumor
and/or nodes
4 4 0 2
Abbreviation: TPZ/CIS, tirapazamine and cisplatin.
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between the primary tumor and nodes (seven nonhypoxic patients
and six hypoxic patients). Hypoxia in the primary tumor is likely to
have far greater implications for locoregional control based on our
findings, possibly because of the fact that residual tumor in nodes can
be removed at neck dissection.
Advantages of hypoxic PET imaging are that it is noninvasive,
permits visualization of both the primary tumor and nodes, and can
detect heterogeneous distribution of hypoxia.27 Fortuitously, the vol-
ume of hypoxic tumor required to permit qualitative detection by
FMISO-PET correlated with the risk of LRF with a standard chemo-
radiotherapy regimen such as chemoboost. Although tumor hypoxia
undoubtedly exists at themicroenvironmental level (which cannot be
detected by PET), it seems that imageable hypoxia is a marker for
failure of reoxygenation. Larger multicenter studies of hypoxic PET
imagingwill be required to confirmourfindings and todetermine the
reproducibility of qualitative methods of assessing tracer uptake or
whetherquantitativemeasuresare required.Suchstudiesarecurrently
under development. The increasing use and availability of PET in
oncology will make it feasible to incorporate a PET hypoxic imaging
test into clinical practice if subsequent studies confirm its utility.
Other noninvasive methods that have been used to detect hy-
poxic tumors include the assessment of proteins that may be upregu-
lated under hypoxic conditions. Variable correlations between
expression of endogenous markers, such as hypoxia-inducible
factor-1 alpha and carbonic anhydrase 9, and adverse outcome with
radiotherapy have been reported.29-33 More recently, Le et al34 have
demonstrated that plasma osteopontin levelsmay correlate with hyp-
oxia and adverse outcome. Subsequently, Overgaard et al35 have
found that high levels of plasma osteopontin correlated with adverse
outcome that was improved in patients who received the hypoxic
radiosensitizer,nimorazole. In theHeadSTARTtrial, thefirstphase III
trial testing TPZ/CIS, plasma and tumor samples have been collected
with a view to assayingmarkers of hypoxia, such as plasma osteopon-
tin, and tissue markers, such as hypoxia-inducible factor-1 alpha and
carbonic anhydrase 9. These ancillary studies will help determine
whether these tests can predict patients most likely to benefit from
the addition of tirapazamine. In addition, a smaller cohort on this
study has also undergone hypoxic PET imaging. This will permit
comparison of PET with plasma and tissuemarkers of hypoxia as a
predictor of outcome.
In head and neck squamous cell carcinoma, hypoxia is common
in patients with locoregionally advanced disease, as shown by our
finding of detectable hypoxia in 71% of patients. However, in other
tumor types or stages with a lower prevalence of hypoxia, testing of
hypoxia-targeted interventions in unselected populations risks miss-
ing a true benefit in patients with hypoxic tumors as well as exposing
patients with nonhypoxic tumors to a potentially more toxic treat-
ment. Therefore, it would be advantageous to enrich the study popu-
lation for patients with hypoxic tumors that wouldmost benefit from
such treatment. PET imaging for hypoxia may provide this ability.
In conclusion, both baseline hypoxia and persistent hypoxia on
FMISOscans inpatients receiving anontirapazamine-containing reg-
imen were associated with a high risk of LRF. Hypoxic PET imaging
with FMISO has considerable promise as a means of identifying pa-
tients who are most likely to benefit from treatment with this
tirapazamine-containing chemoradiotherapy regimen while sparing
patients without hypoxic tumors, who are likely to do well with stan-
dard treatment, any unnecessary additional toxicity.
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